TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Trial to Assess the Effects of Topical Lotions on Changes in the Skin Microbiome and Associations With Itch

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Mild to moderate eczema, as determined by the investigator (score of 2.0-7.5 on Rajka-Langeland severity index).~* Has 1 target lesion, as determined by the investigator (score of 6-12 on Atopic Dermatitis Severity Index (ADSI) and sub-score of at least 2 on erythema and pruritus).~* Experienced a recent itch flare up and is experiencing pre-flare up symptoms at screening.~* Did not use moisturizer on the face and body for 3 days prior to screening.~* Has a score of at least 4.0 on Visual Analog Scale (VAS) Itch Assessment scale at baseline.~* Generally in good health.~* Willing to stop using all topical emollients, moisturizers, and/or other skin barrier creams and/or emulsion treatments for the eczema condition during the test period.~* Willing and able to follow all study directions, including avoiding excessive sun exposure (including tanning beds), and to commit to all follow up visits for the duration of the study.~* Completed informed consent/assent process and signed photograph release.~* Must agree to practice a medically acceptable form of birth control.~Exclusion Criteria:~* Known allergies or sensitivities to test product ingredients.~* Severe eczema.~* Using a therapeutic (over the counter or prescription) body wash that contains an active ingredient for eczema.~* Has a health condition or skin condition that the study investigator thinks could increase risk to the subject or confuse study results (e.g. immune deficiency disorders).~* Has been using that the study investigator thinks could increase risk to the subject or confuse study results (e.g. corticosteroids, immunosuppressive medications).~* Currently participating in another study.~* Subjects who have clinically active bacterial, fungal, or viral skin infections or those who are susceptible to cutaneous infections.~* Has any planned surgery and/or invasive medical procedures scheduled during the course of the study.

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- OTC Eczema Moisturizer Regimen (Type: EXPERIMENTAL): Subjects who were assigned to use an over-the-counter (OTC), oatmeal-containing eczema therapy moisturizing cream. The product is classified as an OTC monograph drug.
- Cosmetic Moisturizer Regimen (Type: EXPERIMENTAL): Subjects who were assigned to use a non-fragranced, dry skin daily moisturizer classified as a cosmetic (i.e. non-OTC).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Innovative Interventions for Smoking Cessation

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* a) Smoking at least 10 cigarettes daily for the past year;~* b) In good physical health;~* c) No contraindications for medicinal nicotine; and~* d) Stable, good mental health.~Exclusion Criteria:~* a) Subjects must not be using other tobacco or nicotine products.~* b) Female subjects cannot be pregnant or nursing and must be using appropriate birth control.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- VLNC Cigarette (Type: ACTIVE_COMPARATOR): Very Low Nicotine Content Cigarette. Dosage: 0.05 mg to 0.09 mg nicotine yield cigarette; Frequency: Daily; Duration: 6 weeks.
- Nicotine Patch (Type: ACTIVE_COMPARATOR): 21 mg nicotine patch. Dosage: 21 mg; Frequency: Daily; Duration: 6 weeks.
- VLNC Cigarette plus Nicotine Patch (Type: EXPERIMENTAL): Very Low Nicotine Content Cigarette plus 21 mg Nicotine Patch. Patch Dosage: 21 mg; Cigarette Dosasge: 0.05 to 0.09 mg nicotine yield; Frequency: Daily; Duration: 6 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Ascending Dosages of Moxidectin and Moxidectin-albendazole Against Trichuris Trichiura

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 7.0

Eligibility Criteria:
Inclusion Criteria:~1. Male and female subjects aged 16 to 18 years, inclusive~2. Written informed consent/assent signed from parent/guardian~3. Positive for T. trichiura by at least two slides of the quadruple Kato-Katz thick smears and infection intensities of at least 100 eggs per gram of stool (EPG)~4. Agree to comply with study procedures, including provision of two stool samples at the beginning (baseline) and approximately three weeks after treatment (follow-up).~Exclusion Criteria:~1. Presence of acute or uncontrolled systemic illnesses (e.g. severe anemia, infection, clinical malaria) as assessed by a medical doctor, upon initial clinical assessment.~2. Known or reported history of chronic illness such as HIV, acute or chronic hepatitis, cancer, diabetes, chronic heart disease or renal disease.~3. Prior treatment with anthelmintics (eg, diethylcarbamazine \[DEC\], suramin, ivermectin or albendazole) within 4 weeks before planned test article administration.~4. Received any investigational drugs or investigational devices within 4 weeks before administration of test article that may confound safety and/or efficacy assessments.~5. Known or suspected allergy to moxidectin, ivermectin or albendazole or other compounds related to these classes of medication.~6. Pregnant (urine testing) or breastfeeding women

- Gender: ALL
- Minimum Age: 16 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Moxidectin 8 mg (Type: EXPERIMENTAL): A single tablet of 8 mg of moxidectin
- Moxidectin 8 mg + Albendazole (Type: EXPERIMENTAL): A single tablet of 8 mg of moxidectin plus a single tablet of albendazole (400 mg)
- Moxidectin 16 mg (Type: EXPERIMENTAL): Two tablets of 8 mg of moxidectin ( = 16 mg)
- Moxidectin 16 mg + Albendazole (Type: EXPERIMENTAL): Two tablets of 8 mg of moxidectin ( = 16 mg) plus a single tablet of albendazole (400 mg)
- Moxidectin 24 mg (Type: EXPERIMENTAL): Three tablets of 8 mg of moxidectin ( = 24 mg)
- Moxidectin 24 mg + Albendazole (Type: EXPERIMENTAL): Three tablets of 8 mg of moxidectin ( = 24 mg) plus a single tablet of albendazole (400 mg)
- Placebo (Type: PLACEBO_COMPARATOR): A single tablet of placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Assessment of Tecfidera® in Radiologically Isolated Syndrome (RIS)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion criteria~1. Males and females meeting 2009 RIS criteria~2. Identified RIS cases with the initial MRI demonstrating anomalies suggestive of demyelinating disease dated \> 2009~3. Incidental anomalies identified on MRI of the brain or spinal cord with the primary reason for the acquired MRI resulting from an evaluation of a process other than MS~4. CNS white matter anomalies meeting the following MRI criteria:~   * Ovoid, well-circumscribed, and homogeneous foci with or without involvement of the corpus callosum~  * T2-hyperintensities measuring \> 3mm2 and fulfilling 3 of 4 Barkhof-Tintoré criteria for dissemination in space~  * CNS anomalies not consistent with a vascular pattern~  * Qualitative determination that CNS anomalies have a characteristic appearance of demyelinating lesions~5. MRI anomalies do not account for clinically apparent neurological impairments in patients~Exclusion criteria~1. Women who are pregnant or nursing~2. Incomplete medical history or radiological data~3. History of remitting clinical symptoms consistent with multiple sclerosis lasting \> 24 hours prior to CNS imaging revealing anomalies suggestive of MS~4. History of paroxysmal symptoms associated with MS (i.e. Lhermitte's or Uhthoff's phenomena)~5. CNS MRI anomalies are better accounted for by another disease process~6. The subject is unwilling or unable to comply with the requirements of the study protocol~7. Exposure to a disease modifying therapy for MS/RIS within the past 3 months~8. Exposure to high-dose glucocorticosteroid treatment within the past 30 days~9. Participation in other clinical trials involving treatment with a disease-modifying agent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tecfidera (Type: ACTIVE_COMPARATOR): Tecfidera (120mg by mouth twice daily for 7 days with dose escalation to 240mg by mouth twice daily)
- Placebo (Type: PLACEBO_COMPARATOR): Placebo by mouth twice daily.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Dexamethasone on Reduction of Macular Thickness in Diabetic Patients, a Randomized Clinical Trial

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* age \> = 18 years;~* diagnosis of DM type 2;~* pseudophakic patients~* presence of clinically significant DME according to ETDRS guidelines;~* best correct visual acuity (BCVA) between 20/400 and 20/40;~* central macular thickness (CMT) \>= 300 µm measured by spectral domain optical coherence tomography ( Spectralis® Heidelberg). If both eyes of the patient met the elegibility criteria, the eye with worse BCVA at baseline was designated as the study eye.~Exclusion Criteria:~* any treatment of DME in the previous 4 months;~* pan retinal photocoagulation (PRP) in the previous 4 months or antecipated need of PRP for the next 6 months;~* any ophthalmologic surgery performed in the previous 4 months;~* history of pars plana vitrectomy;~* history of open-angle glaucoma or intraocular pressure elevation induced by corticosteroids that required anti-glaucomatous treatment or anti- hypertensive ocular treatment;~* intraocular pressure \>= 21 mmHg;~* patients with characteristics that meet the inclusion criteria, but refused to sign the written general consent.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- 0,01ml dexamethasone solution (Type: EXPERIMENTAL): One intravitreous injection of 0,01 ml dexamethasone solution 4 mg/ml.
- 0,03 ml dexamethasone solution (Type: EXPERIMENTAL): One intravitreous injection of 0,03 ml dexamethasone solution 4 mg/ml.
- 0,05 ml dexamethasone solution (Type: EXPERIMENTAL): One intravitreous injection of 0,05 ml dexamethasone solution 4 mg/ml.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of Women After Postpartum Haemorrhage

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Women with PPH ≥ 700 and ≤ 1000 mL or PPH \> 1000 mL and Hb \> 6.5 g/dL (4.0 mmol/L) measured \> 12 hours after delivery~2. Willingness to participate and signed the informed consent form~Exclusion Criteria:~1. Women aged \< 18 years~2. Multiple births~3. Peripartum RBC transfusion~4. Known iron overload or disturbances in utilisation of iron (e.g. haemochromatosis and haemosiderosis)~5. Known hypersensitivity to parenteral iron or any excipients in the investigational drug products~6. Women with a history of active asthma within the last 5 years or a history of multiple allergies~7. Known decompensated liver cirrhosis and active hepatitis~8. Women with HELLP (Haemolysis Elevated Liver enzymes Low Platelet count) syndrome (defined according to Dansk Selskab for Obstetrik og Gynækologi guidelines)~9. Active acute infection assessed by clinical judgement~10. Rheumatoid arthritis with symptoms or signs of active joint inflammation~11. History of anaemia caused by e. g. thalassemia, hypersplenism or haemolytic anaemia (known haematologic disorder other than iron deficiency)~12. Not able to read, speak and understand the Danish language~13. Participation in any other clinical study where the study drug has not passed 5 half-lives prior to the baseline~14. Any other medical condition that, in the opinion of the Investigator, may cause the patient to be unsuitable for completion of the study or place the patient at potential risk from being in the study. For example, a malignancy, uncontrolled hypertension, unstable ischaemic heart disease or uncontrolled diabetes mellitus

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Iron isomaltoside 1000 (Monofer®) (Type: EXPERIMENTAL): None
- Standard medical Care (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Enteric-Coated Mycophenolate Sodium (EC-MPS) in Renal Transplant Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
De Novo-Inclusion criteria~1. Males and females aged 6 years or over.~2. Recipients of cadaveric, living unrelated or living related kidney transplant, treated with CsA-Me, with or without corticosteroids, as primary immunosuppression.~Maintenance-Inclusion criteria~1. Males and females aged 6 years or over.~2. Recipients of first or secondary cadaveric, living related or unrelated donor kidney transplant.~3. Patients currently receiving CsA-ME with or without Mycophenolate mofetil (MMF) or azathioprine, with or without corticosteroids as part of their immunosuppressive regimen for at least 3 months prior to Screening.~4. Patients in a stable condition in terms of graft function (serum creatinine not above 2.3 mg/dL (=204 µmol/L) at screening and at baseline, or not increased by more than 20% at baseline compared to values obtained at screening), no change of immune suppressive regimen due to graft malfunction, and any known clinically significant physical and/or laboratory changes for at least 2 months prior to enrollment.~De Novo and Maintenance-Exclusion Criteria~1. Multi-organ recipients (e.g. kidney and pancreas) or previous transplant with any organ other than kidney.~2. Patients with any known hypersensitivity to MPA, EC-MPS or other components of the formulation (e.g. lactose).~3. Patients with thrombocytopenia (\< 75,000/mm3), with an absolute neutrophil count of \< 1,500/mm3, and/or leukocytopenia (\< 2,500/mm3), and/or hemoglobin \< 6 g/dL at Screening or Baseline.~4. Patients with a history of malignancy within the last five years, except excised squamous or basal cell carcinoma of the skin.~Other protocol-defined inclusion/exclusion criteria may apply

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: None
- Healthy Volunteers: None

Study Arms:
- EC-MPS (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Serratus Anterior Plane Block in Patients Undergoing Mastectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Adult patients 18 years or older~2. Individuals undergoing either a mastectomy or mastectomy with tissue expander for which the anesthetic plan includes a serratus anterior plane block.~Exclusion Criteria:~1. Any known sensory deficit of the anterolateral chest wall.~2. Any local disorder of the skin or otherwise where blockade is to be performed which would prevent safe performance of the block~3. Pregnancy~4. American Society of Anesthesiology classification greater than 3~5. Allergy to amide local anesthetic medications~6. Chronic pain conditions~7. Preoperative opioid use greater than 20 oral morphine equivalents per day~8. Any coagulation abnormality which would be a contraindication for block placement~9. Preoperative chronic renal dysfunction requiring renal replacement therapy or a serum creatinine greater than 1.4 mg/dL~10. Body mass index \>50~11. Incarceration~12. Inability to understand study procedures including inability to understand the English language~13. Inability to provide adequate informed consent~14. Refusal to participate in the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sub-serratus regional block (Type: EXPERIMENTAL): A regional block using of ropivacaine 0.35% (30 mL will be used per side in patients weighing over 60 kg and 20 mL will be used in patients weighing less than 60 kg) will be administered to the injection site deep to the serratus anterior muscle.
- Supra-serratus regional block (Type: ACTIVE_COMPARATOR): A regional block using of ropivacaine 0.35% (30 mL will be used per side in patients weighing over 60 kg and 20 mL will be used in patients weighing less than 60 kg) will be administered to the injection site superficial to the serratus anterior muscle.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Single Injection Adductor Canal Block vs Catheter for Total Knee Arthroplasty

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients over or equal to the age of 18 years old who can understand the study protocol and are able to give consent~* Patients with an American Society of Anaesthesiology (ASA) classification 1 to 3~* Patients must have a preoperative oral 24 hour opioid consumption of less than or equal to 30 mg morphine equivalents~* Patients must be able to understand and be able to use patient controlled analgesia~* Patients must be undergoing a primary total knee arthroplasty with neuraxial anesthesia~Exclusion Criteria:~* Patients with a contraindication to neuraxial and/or regional anaesthesia~* Patients with an allergy to local anaesthetics~* Patients who have chronic pain not related to their knee joint~* Patients with chronic opioid use (daily or almost daily use \>3 months)~* Patients with contraindications to dexamethasone (allergy, infection, Insulin dependent Diabetes Mellitus)~* Patients with pre-existing neuropathy~* Patients with hepatic failure~* Patients with renal failure with eGFR\<60~* Patients with allergy to ketorolac or NSAIDs

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 100 Years
- Healthy Volunteers: f

Study Arms:
- Adductor Canal block (Type: ACTIVE_COMPARATOR): Postoperatively in the PACU, this group will receive 20ml 0.5% ropivacaine for their ACB.
- Adductor canal block with dexamethasone (Type: ACTIVE_COMPARATOR): Postoperatively in the PACU, this group will receive 20ml 0.5% ropivacaine for their ACB along with 8mg IV dexamethasone.
- Adductor canal catheter (Type: ACTIVE_COMPARATOR): Postoperatively in the PACU, this group will receive 20ml 0.5% ropivacaine for their adductor canal block and have a catheter placed in the adductor canal at the mid-thigh. 0.2% ropivacaine at 5ml/hr will be run for 48 hours.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: ENDObesity® II Study: TransPyloric Shuttle® System for Weight Loss

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female subjects between the ages of 22 to 60~* A BMI between 30.0 to 40.0 kg/m2, inclusive. Subjects with a BMI of 30.0 kg/m2 to 34.9 kg/m2 are required to have one or more obesity-related comorbidities~* History of obesity for at least 2 years, with history of failure of medically or commercially supervised weight loss program~* \< 5% change in body weight for at least 3 months~* Negative pregnancy test, agree to be on birth control for the duration of participation~* Informed consent~* Willing and able to comply with study procedures~Exclusion Criteria:~* Pregnancy or nursing~* Hormonal or genetic cause for obesity~* Prior history of any GI surgery or endoscopic intervention~* Chronic use of medications likely to contribute to weight gain or prevent weight loss~* Gastric or duodenal ulcers~* Positive for H. pylori~* History of severe dyspepsia~* GI tract motility disorders~* History of inflammatory disease of GI tract, coeliac disease, pancreatitis, portal hypertension, cirrhosis, and/or varices~* Diabetes treated with insulin~* HbA1c \>7.5%~* Uncontrolled thyroid and adrenal gland disease or uncontrolled hypertension~* History of certain cardiac events~* Localized or systemic infection~* Anemia~* History of asthma likely to require systemic steroid therapy~* Autoimmune connective tissue disorders or immunocompromised~* History of malignancy except non-melanoma skin cancer~* Continuous use of ulcerogenic medication~* On anticoagulation or antiplatelet therapy~* Use of weight-loss medication~* In other weight-loss program~* Unable to take proton pump inhibitor~* Abnormal laboratory values or EKG~* Inability to walk at least 0.8 kilometers per day~* Planned surgical procedure that can impact the conduct of the study~* Known allergy to any component materials in the TPSS~* Smoker or user of nicotine product~* Substance abuse~* Severe, uncontrolled psychiatric illness~* Recent inpatient psychiatric treatment~* Moderate depression~* Bulimia nervosa or binge eating disorder~* Participation in another clinical study~* Employee or family member of Sponsor or study staff~* Have any endoscopic exclusion criteria

- Gender: ALL
- Minimum Age: 22 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- TransPyloric Shuttle (TPS) (Type: EXPERIMENTAL): TransPyloric Shuttle plus Lifestyle Counseling
- Control (Type: SHAM_COMPARATOR): Sham procedure plus Lifestyle Counseling

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete